Methods of modulating smyd3 for treatment of cancer

Abstract

The present invention features a method for determining the methyltransferase activity of a polypeptide and screening for modulators of methyltransferase activity, more particularly for modulators of the methylation of retinoblastoma by SMYD3. The invention further provides a method or pharmaceutical composition for prevention or treating of colorectal cancer, hepatocellular carcinoma, bladder cancer and/or breast cancer using a modulator so identified.

1 .- 6 . (canceled) 
     
     
         7 . A method of screening for a compound for treating a cancer selected from group consisting of colorectal cancer, hepatocellular carcinoma, bladder cancer, and breast cancer, said method comprising the steps of:
 a. identifying a test compound that modulates methylation of a retinoblastoma peptide by SMYD3 according to a method comprising the steps of:
 1) contacting an SMYD3 polypeptide having a methyltransferase activity selected from the group consisting of:
 i. a polypeptide comprising the amino acid sequence of SEQ ID NO: 2; 
 ii. a polypeptide that comprises the amino acid sequence of positions 117 to 246 of the amino acid sequence of SEQ ID NO: 2, wherein said polypeptide has a methyltransferase activity equivalent to the polypeptide consisting of the amino acid sequence of SEQ ID NO: 2; 
 iii. a polypeptide that comprises the amino acid sequence of positions 1 to 250 of the amino acid sequence of SEQ ID NO: 2; 
 vi. a polypeptide that comprises the amino acid sequence of positions 45 to 428 of the amino acid sequence of SEQ ID NO: 2; 
 v. a polypeptide that comprises the amino acid sequence of SEQ ID NO: 2 in which the amino acids of positions 1 to 30 have been deleted; 
 vi. a polypeptide that comprises the amino acid sequence of SEQ ID NO: 2 in which the amino acids of positions 1 to 44 are deleted; 
 vii. a polypeptide that comprises the amino acid sequence of SEQ ID NO: 2 in which the amino acids of positions 1 to 20 are deleted; 
 viii. a polypeptide that comprises the amino acid sequence of SEQ ID NO: 2 in which the amino acids of positions 1 to 10 are deleted; 
 
 with a retinoblastoma peptide to be methylated and a cofactor in the presence of the test compound under conditions suitable for methylation of the retinoblastoma peptide; 
   2) detecting the methylation level of the retinoblastoma peptide; and   3) comparing the methylation level of step 2) with a control level detected in the absence of the test compound, and
 b. selecting the test compound that decreases the methylation level of the retinoblastoma peptide to be methylated as compared to a control methylation level detected in the absence of the test compound. 
   
     
     
         8 .- 21 . (canceled) 
     
     
         22 . The method of  claim 7 , wherein the retinoblastoma peptide comprises the amino acid sequence of SEQ ID NO: 4, or a functional mutant comprising the amino acid sequence of SEQ ID NO: 4, including one or more of the following mutations: K889A, K896A, K791A, K814A, K791A and K824A, and K814A and K824A, or is a functional fragment consisting of the amino acid sequence of positions 769-921 of the amino acid sequence of SEQ ID NO: 4. 
     
     
         23 . The method of  claim 7 , wherein said cofactor is S-adenosyl homocysteine hydrolase (SAHH).